NASDAQ:CDTX - Cidara Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.25 +0.35 (+7.14 %)
(As of 05/23/2018 03:07 PM ET)
Previous Close$4.95
Today's Range$4.95 - $5.40
52-Week Range$3.70 - $8.80
Volume7,569 shs
Average Volume119,246 shs
Market Capitalization$97.33 million
P/E Ratio-1.68
Dividend YieldN/A
Beta2.05

About Cidara Therapeutics (NASDAQ:CDTX)

Cidara Therapeutics logoCidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. It is also developing antibody-drug conjugates for multidrug-resistant bacterial infections that directly kill pathogens and also direct a patient's immune system to attack and eliminate bacterial, fungal, or viral pathogens. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.

Receive CDTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CDTX
CUSIPN/A
Phone858-752-6170

Debt

Debt-to-Equity Ratio0.15
Current Ratio5.99
Quick Ratio5.99

Price-To-Earnings

Trailing P/E Ratio-1.68
Forward P/E Ratio-1.94
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.38 per share
Price / Book2.21

Profitability

EPS (Most Recent Fiscal Year)($3.18)
Net Income$-55,720,000.00
Net MarginsN/A
Return on Equity-106.22%
Return on Assets-79.34%

Miscellaneous

Employees61
Outstanding Shares21,390,000

Cidara Therapeutics (NASDAQ:CDTX) Frequently Asked Questions

What is Cidara Therapeutics' stock symbol?

Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."

How were Cidara Therapeutics' earnings last quarter?

Cidara Therapeutics (NASDAQ:CDTX) issued its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.80) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.70) by $0.10. View Cidara Therapeutics' Earnings History.

What price target have analysts set for CDTX?

3 brokerages have issued 1-year target prices for Cidara Therapeutics' shares. Their predictions range from $15.00 to $16.00. On average, they anticipate Cidara Therapeutics' share price to reach $15.50 in the next twelve months. View Analyst Ratings for Cidara Therapeutics.

What are Wall Street analysts saying about Cidara Therapeutics stock?

Here are some recent quotes from research analysts about Cidara Therapeutics stock:
  • 1. According to Zacks Investment Research, "Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. " (5/15/2018)
  • 2. Cantor Fitzgerald analysts commented, "Positives from the quarter that support our thesis: 1) On 11/28/17, Cidara announced the completion of patient enrollment in its Phase 2 STRIVE trial for rezafungin (formerly CD101 IV) to treat patients with candidemia and invasive candidiasis, 2) in January 2018, Cidara presented data highlighting the potential advantages of rezafungin for the treatment and prevention of invasive fungal infections in immunocompromised patients at the 8th AAA Conference and 2018 BMT Tandem Meetings, 3) in January 2018, Cidara announced that a supplement to the Journal of Antimicrobial Chemotherapy was published, providing insight into the future of echinocandin therapy, including strategies for the treatment and prevention of life-threatening invasive fungal infections, 4) in October 2017, Cidara received ~$20MM in gross proceeds from a private placement, 5) in October 2017, Cidara presented preclinical rezafungin data in six presentations at ID Week 2017 and at the 8th Trends in Medical Mycology meeting highlighting rezafungin’s potential advantages, and 6) cash and equivalents totaled $75.3MM as of 12/31/17." (2/27/2018)

Who are some of Cidara Therapeutics' key competitors?

Who are Cidara Therapeutics' key executives?

Cidara Therapeutics' management team includes the folowing people:
  • Dr. Jeffrey L. Stein, CEO, Pres & Exec. Director (Age 63)
  • Mr. Matthew W. Onaitis, CFO, Principal Accounting Officer, Gen. Counsel & Sec. (Age 47)
  • Mr. Neil Abdollahian, Chief Bus. Officer (Age 45)
  • Dr. Kevin M. Forrest Ph.D., Founder and Chief Strategy Officer (Age 41)
  • Dr. Kenneth F. Bartizal Ph.D., Chief Devel. Officer (Age 67)

When did Cidara Therapeutics IPO?

(CDTX) raised $60 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

Has Cidara Therapeutics been receiving favorable news coverage?

Media stories about CDTX stock have trended somewhat positive on Wednesday, according to Accern. Accern identifies negative and positive media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cidara Therapeutics earned a news impact score of 0.06 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 46.30 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Cidara Therapeutics' major shareholders?

Cidara Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FRAZIER HEALTHCARE VII, L.P. (6.48%), Prosight Management LP (5.54%), BlackRock Inc. (1.17%), Guggenheim Capital LLC (1.05%), JPMorgan Chase & Co. (0.32%) and Trellus Management Company LLC (0.22%). Company insiders that own Cidara Therapeutics stock include Jeffrey Stein, Kevin Forrest, Target N V Biotech and Taylor Sandison. View Institutional Ownership Trends for Cidara Therapeutics.

Which institutional investors are selling Cidara Therapeutics stock?

CDTX stock was sold by a variety of institutional investors in the last quarter, including Prosight Management LP and Trellus Management Company LLC. View Insider Buying and Selling for Cidara Therapeutics.

Which institutional investors are buying Cidara Therapeutics stock?

CDTX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Guggenheim Capital LLC, JPMorgan Chase & Co., Northern Trust Corp and Trexquant Investment LP. Company insiders that have bought Cidara Therapeutics stock in the last two years include Jeffrey Stein, Kevin Forrest, Target N V Biotech and Taylor Sandison. View Insider Buying and Selling for Cidara Therapeutics.

How do I buy shares of Cidara Therapeutics?

Shares of CDTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cidara Therapeutics' stock price today?

One share of CDTX stock can currently be purchased for approximately $5.25.

How big of a company is Cidara Therapeutics?

Cidara Therapeutics has a market capitalization of $97.33 million. The biotechnology company earns $-55,720,000.00 in net income (profit) each year or ($3.18) on an earnings per share basis. Cidara Therapeutics employs 61 workers across the globe.

How can I contact Cidara Therapeutics?

Cidara Therapeutics' mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-752-6170 or via email at [email protected]


MarketBeat Community Rating for Cidara Therapeutics (CDTX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  247 (Vote Outperform)
Underperform Votes:  170 (Vote Underperform)
Total Votes:  417
MarketBeat's community ratings are surveys of what our community members think about Cidara Therapeutics and other stocks. Vote "Outperform" if you believe CDTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cidara Therapeutics (NASDAQ:CDTX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Cidara Therapeutics in the last 12 months. Their average twelve-month price target is $15.50, suggesting that the stock has a possible upside of 195.24%. The high price target for CDTX is $16.00 and the low price target for CDTX is $15.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.803.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $15.50$16.00$13.50$13.85
Price Target Upside: 195.24% upside159.32% upside87.50% upside68.90% upside

Cidara Therapeutics (NASDAQ:CDTX) Consensus Price Target History

Price Target History for Cidara Therapeutics (NASDAQ:CDTX)

Cidara Therapeutics (NASDAQ:CDTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/23/2018WBB SecuritiesUpgradeHold ➝ BuyLowView Rating Details
5/10/2018Cantor FitzgeraldSet Price TargetBuy$15.00MediumView Rating Details
11/9/2017HC WainwrightBoost Price TargetBuy$14.00 ➝ $16.00N/AView Rating Details
5/16/2017WedbushReiterated RatingOutperform$13.00LowView Rating Details
4/29/2017BTIG ResearchReiterated RatingBuy$15.00 ➝ $20.00LowView Rating Details
4/20/2017Raymond JamesInitiated CoverageStrong-Buy$14.00HighView Rating Details
4/12/2017Ladenburg ThalmannInitiated CoverageBuy ➝ Buy$11.25LowView Rating Details
4/10/2017Needham & Company LLCReiterated RatingBuy$10.00MediumView Rating Details
3/24/2017Jefferies GroupReiterated RatingBuy$15.00HighView Rating Details
12/21/2016Leerink SwannInitiated CoverageOutperform$17.00N/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Cidara Therapeutics (NASDAQ:CDTX) Earnings History and Estimates Chart

Earnings by Quarter for Cidara Therapeutics (NASDAQ:CDTX)

Cidara Therapeutics (NASDAQ:CDTX) Earnings Estimates

2018 EPS Consensus Estimate: ($2.76)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.78)($0.63)($0.71)
Q2 20182($0.79)($0.46)($0.63)
Q3 20182($0.80)($0.66)($0.73)
Q4 20182($0.80)($0.59)($0.70)

Cidara Therapeutics (NASDAQ CDTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2018Q1 2018($0.6960)($0.80)$0.78 millionViewN/AView Earnings Details
2/27/2018Q4 2017($0.7420)($0.69)$0.78 millionViewN/AView Earnings Details
11/8/2017Q3 2017($0.94)($0.73)$0.18 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.91)($0.99)$0.25 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.90)($0.80)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.79)($0.88)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.8920)($0.88)ViewN/AView Earnings Details
8/11/2016Q2($0.76)($0.85)ViewN/AView Earnings Details
5/12/2016Q1($0.7630)($0.71)ViewN/AView Earnings Details
3/18/2016Q4 2015($0.70)($0.72)ViewN/AView Earnings Details
11/16/2015Q3($0.57)($0.67)ViewListenView Earnings Details
8/11/2015Q2 2015($0.59)($0.59)ViewN/AView Earnings Details
5/21/2015Q1 2015($0.80)($5.92)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Cidara Therapeutics (NASDAQ:CDTX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Cidara Therapeutics (NASDAQ CDTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.20%
Institutional Ownership Percentage: 62.48%
Insider Trading History for Cidara Therapeutics (NASDAQ:CDTX)
Institutional Ownership by Quarter for Cidara Therapeutics (NASDAQ:CDTX)

Cidara Therapeutics (NASDAQ CDTX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/15/2017Target N V BiotechMajor ShareholderBuy60,000$7.57$454,200.002,295,272View SEC Filing  
9/12/2017Jeffrey SteinCEOBuy7,350$6.79$49,906.5051,851View SEC Filing  
6/7/2017Taylor SandisonInsiderBuy20,000$5.90$118,000.00View SEC Filing  
6/5/2017Jeffrey SteinCEOBuy15,000$5.95$89,250.00View SEC Filing  
3/31/2017Jeffrey SteinCEOBuy12,900$7.75$99,975.00View SEC Filing  
3/31/2017Kevin ForrestInsiderBuy12,500$7.75$96,875.00View SEC Filing  
5/20/2016Jeffrey SteinCEOBuy4,310$11.51$49,608.1012,100View SEC Filing  
5/20/2016Kevin ForrestCFOBuy4,356$11.53$50,224.6858,253View SEC Filing  
11/25/2015Jeffrey SteinCEOBuy6,700$15.09$101,103.006,700View SEC Filing  
11/23/2015Kevin ForrestCFOBuy7,087$14.23$100,848.0151,719View SEC Filing  
4/20/2015Timothy R FransonDirectorBuy4,000$16.00$64,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cidara Therapeutics (NASDAQ CDTX) News Headlines

Source:
DateHeadline
Cidara Therapeutics (CDTX) Upgraded to Buy at WBB SecuritiesCidara Therapeutics (CDTX) Upgraded to Buy at WBB Securities
www.americanbankingnews.com - May 23 at 11:54 AM
Data to be Presented at ASM Microbe 2018 Demonstrate the Efficacy and Safety of Cidara’s Rezafungin for the Treatment of Invasive Fungal InfectionsData to be Presented at ASM Microbe 2018 Demonstrate the Efficacy and Safety of Cidara’s Rezafungin for the Treatment of Invasive Fungal Infections
finance.yahoo.com - May 23 at 9:29 AM
Cidara Therapeutics and Rutgers University awarded $5.5M grant from NIH to develop immunotherapy agents targeting gram-negative bacterial infectionsCidara Therapeutics and Rutgers University awarded $5.5M grant from NIH to develop immunotherapy agents targeting gram-negative bacterial infections
seekingalpha.com - May 21 at 9:53 AM
Cidara Therapeutics Announces Offering of Common Stock and WarrantsCidara Therapeutics Announces Offering of Common Stock and Warrants
finance.yahoo.com - May 21 at 9:53 AM
Cidara Therapeutics and Rutgers University Awarded $5.5 Million Grant from NIH to Support Development of Novel Immunotherapy Agents Targeting Multi-drug Resistant Gram-negative Bacterial InfectionsCidara Therapeutics and Rutgers University Awarded $5.5 Million Grant from NIH to Support Development of Novel Immunotherapy Agents Targeting Multi-drug Resistant Gram-negative Bacterial Infections
finance.yahoo.com - May 21 at 9:53 AM
Cidara Therapeutics (CDTX) Expected to Post Earnings of -$0.65 Per ShareCidara Therapeutics (CDTX) Expected to Post Earnings of -$0.65 Per Share
www.americanbankingnews.com - May 18 at 1:43 PM
Cidara Therapeutics (CDTX) Cut to Sell at Zacks Investment ResearchCidara Therapeutics (CDTX) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - May 15 at 8:15 PM
Cidara Therapeutics (CDTX) Releases  Earnings Results, Misses Estimates By $0.10 EPSCidara Therapeutics (CDTX) Releases Earnings Results, Misses Estimates By $0.10 EPS
www.americanbankingnews.com - May 11 at 4:37 PM
Cidara Therapeutics (CDTX) Given a $15.00 Price Target by Cantor Fitzgerald AnalystsCidara Therapeutics (CDTX) Given a $15.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - May 11 at 3:57 PM
Cidara Therapeutics misses by $0.15Cidara Therapeutics misses by $0.15
seekingalpha.com - May 11 at 11:07 AM
Cidara Therapeutics: 1Q Earnings SnapshotCidara Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 11 at 11:07 AM
Cidara Provides Corporate Update and Reports First Quarter 2018 Financial ResultsCidara Provides Corporate Update and Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 11 at 11:07 AM
Cidara Therapeutics (CDTX) Upgraded at ValuEngineCidara Therapeutics (CDTX) Upgraded at ValuEngine
www.americanbankingnews.com - May 3 at 10:19 PM
Cidara Therapeutics (CDTX) Downgraded by Zacks Investment ResearchCidara Therapeutics (CDTX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 1 at 9:52 PM
Cidara Therapeutics (CDTX) Receives Consensus Recommendation of "Hold" from AnalystsCidara Therapeutics (CDTX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 30 at 5:34 PM
Cidara Therapeutics (CDTX) Given Average Recommendation of "Buy" by BrokeragesCidara Therapeutics (CDTX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 5 at 3:34 PM
Cidara Therapeutics to Present Rezafungin Data at the European Congress of Clinical Microbiology and Infectious Diseases 2018 MeetingCidara Therapeutics to Present Rezafungin Data at the European Congress of Clinical Microbiology and Infectious Diseases 2018 Meeting
finance.yahoo.com - April 4 at 5:25 PM
Cidara Therapeutics (CDTX) Price Target Increased to $16.00 by Analysts at HC WainwrightCidara Therapeutics (CDTX) Price Target Increased to $16.00 by Analysts at HC Wainwright
www.americanbankingnews.com - March 31 at 5:28 PM
Cidara Therapeutics (CDTX) Provides Clinical Data Updates for its Lead Antifungal RezafunginCidara Therapeutics (CDTX) Provides Clinical Data Updates for its Lead Antifungal Rezafungin
www.streetinsider.com - March 22 at 9:51 AM
Cidara Therapeutics Provides Clinical Data Updates for its Lead Antifungal RezafunginCidara Therapeutics Provides Clinical Data Updates for its Lead Antifungal Rezafungin
globenewswire.com - March 21 at 10:49 AM
Blog Exposure - Cidara Therapeutics Released Positive Top-line Results from Phase-2 STRIVE Trial Assessing its Lead Antifungal RezafunginBlog Exposure - Cidara Therapeutics Released Positive Top-line Results from Phase-2 STRIVE Trial Assessing its Lead Antifungal Rezafungin
finance.yahoo.com - March 21 at 10:49 AM
Cidara Therapeutics Provides Clinical Data Updates for its Lead Antifungal RezafunginCidara Therapeutics Provides Clinical Data Updates for its Lead Antifungal Rezafungin
finance.yahoo.com - March 21 at 10:49 AM
Cidara Therapeutics Sinks Despite Positive Midstage ResultsCidara Therapeutics Sinks Despite Positive Midstage Results
247wallst.com - March 19 at 4:13 PM
Cantor Fitzgerald Analysts Give Cidara Therapeutics (CDTX) a $15.00 Price TargetCantor Fitzgerald Analysts Give Cidara Therapeutics (CDTX) a $15.00 Price Target
www.americanbankingnews.com - March 19 at 12:30 PM
Cidara Therapeutics Reports Positive Topline Results from Phase 2 STRIVE Trial of Lead Antifungal RezafunginCidara Therapeutics Reports Positive Topline Results from Phase 2 STRIVE Trial of Lead Antifungal Rezafungin
finance.yahoo.com - March 19 at 10:37 AM
Cidara Therapeutics stock soars toward 13-month high after positive drug trial resultsCidara Therapeutics' stock soars toward 13-month high after positive drug trial results
finance.yahoo.com - March 19 at 10:37 AM
Options Traders Expect Huge Moves in Cidara Therapeutics (CDTX) StockOptions Traders Expect Huge Moves in Cidara Therapeutics (CDTX) Stock
finance.yahoo.com - March 19 at 10:37 AM
Cidara Therapeutics to Present Rezafungin Data at the European Society for Blood and Marrow Transplantation 2018 MeetingCidara Therapeutics to Present Rezafungin Data at the European Society for Blood and Marrow Transplantation 2018 Meeting
finance.yahoo.com - March 16 at 10:58 AM
Cidara Therapeutics Inc (CDTX) Receives Average Rating of "Buy" from AnalystsCidara Therapeutics Inc (CDTX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 11 at 5:54 PM
Prosight Management LP Purchases New Holdings in Cidara Therapeutics Inc (CDTX)Prosight Management LP Purchases New Holdings in Cidara Therapeutics Inc (CDTX)
www.americanbankingnews.com - March 5 at 4:07 PM
Cidara Therapeutics Inc Expected to Earn FY2018 Earnings of ($2.38) Per Share (CDTX)Cidara Therapeutics Inc Expected to Earn FY2018 Earnings of ($2.38) Per Share (CDTX)
www.americanbankingnews.com - March 5 at 6:42 AM
Leerink Swann Analysts Boost Earnings Estimates for Cidara Therapeutics Inc (CDTX)Leerink Swann Analysts Boost Earnings Estimates for Cidara Therapeutics Inc (CDTX)
www.americanbankingnews.com - March 5 at 2:40 AM
Broadfin Capital LLC Has $5.83 Million Stake in Cidara Therapeutics Inc (CDTX)Broadfin Capital LLC Has $5.83 Million Stake in Cidara Therapeutics Inc (CDTX)
www.americanbankingnews.com - March 3 at 4:53 AM
Cidara Announces Appointment of Chrysa Mineo as Independent DirectorCidara Announces Appointment of Chrysa Mineo as Independent Director
finance.yahoo.com - March 2 at 10:13 AM
Cidara Therapeutics (CDTX) Issues  Earnings ResultsCidara Therapeutics (CDTX) Issues Earnings Results
www.americanbankingnews.com - March 1 at 11:06 AM
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial ResultsCidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 28 at 4:11 PM
Cidara Therapeutics (CDTX) Receives "Buy" Rating from Cantor FitzgeraldCidara Therapeutics (CDTX) Receives "Buy" Rating from Cantor Fitzgerald
www.americanbankingnews.com - February 27 at 10:48 PM
Reviewing Cidara Therapeutics (CDTX) & Paratek Pharmaceuticals (PRTK)Reviewing Cidara Therapeutics (CDTX) & Paratek Pharmaceuticals (PRTK)
www.americanbankingnews.com - February 19 at 3:20 PM
Cidara Therapeutics Inc (CDTX) Receives Average Rating of "Buy" from BrokeragesCidara Therapeutics Inc (CDTX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 14 at 3:26 PM
The Antimicrobials Working Group Announces the Appointment of Dr. Michael Dunne as Vice ChairThe Antimicrobials Working Group Announces the Appointment of Dr. Michael Dunne as Vice Chair
finance.yahoo.com - January 30 at 3:19 PM
Cidara Therapeutics Announces Presentations at the 8th Advances Against Aspergillosis Conference and 2018 BMT Tandem MeetingCidara Therapeutics Announces Presentations at the 8th Advances Against Aspergillosis Conference and 2018 BMT Tandem Meeting
finance.yahoo.com - January 29 at 3:20 PM
Cidara Therapeutics Inc (CDTX) Receives Average Recommendation of "Buy" from BrokeragesCidara Therapeutics Inc (CDTX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 20 at 5:38 PM
Cidara Therapeutics (CDTX) Stock Rating Reaffirmed by Cantor FitzgeraldCidara Therapeutics (CDTX) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - January 19 at 11:38 AM
Cidara Therapeutics (CDTX) Lowered to Hold at Zacks Investment ResearchCidara Therapeutics (CDTX) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 12 at 7:26 PM
Cidara Therapeutics (CDTX) Upgraded by Zacks Investment Research to "Buy"Cidara Therapeutics (CDTX) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - January 9 at 7:12 PM
Head-To-Head Contrast: Cidara Therapeutics (CDTX) versus Its CompetitorsHead-To-Head Contrast: Cidara Therapeutics (CDTX) versus Its Competitors
www.americanbankingnews.com - January 5 at 3:32 AM
Expansion Therapeutics Raises $55.3 Million in Series A Financing to Advance Portfolio of Novel RNA Targeted Small Molecule Medicines to Treat Rare DiseasesExpansion Therapeutics Raises $55.3 Million in Series A Financing to Advance Portfolio of Novel RNA Targeted Small Molecule Medicines to Treat Rare Diseases
www.businesswire.com - January 4 at 9:52 AM
Newly Published Journal of Antimicrobial Chemotherapy Supplement Provides Insights into the Future of Echinocandin Therapy for Invasive Fungal InfectionsNewly Published Journal of Antimicrobial Chemotherapy Supplement Provides Insights into the Future of Echinocandin Therapy for Invasive Fungal Infections
finance.yahoo.com - January 4 at 9:52 AM
Cidara Therapeutics Inc (CDTX) Given Consensus Recommendation of "Buy" by BrokeragesCidara Therapeutics Inc (CDTX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - December 26 at 4:39 PM
Cidara Therapeutics (CDTX) Downgraded to Hold at Zacks Investment ResearchCidara Therapeutics (CDTX) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - December 25 at 7:14 PM

SEC Filings

Cidara Therapeutics (NASDAQ:CDTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cidara Therapeutics (NASDAQ:CDTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cidara Therapeutics (NASDAQ CDTX) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.